Nanologix is a biotechnology company focused on sale of Petri plates packaged in an exclusive licensed Flatpack and the BNP rapid detection technology for bacteria, mold, and spores.
NanoLogix technology is used to test for bacteria and other microorganisms and in some cases, dependent upon the technology used, provide for early detection of bacteria and other microorganisms present in infectious and noninfectious human diseases, the environment, industrial and manufacturing settings, veterinary medicine, and research and testing laboratories.
NanoLogix began 26 years ago under the name Infectech. From its founding through 2007 the Company had been issued patents that were in some cases practically, and in other cases theoretically, applicable in the areas of applied microbiology, soil microbiology, medical diagnostics, microbial physiology, pharmacology, pharmaco-kinetics, and determination of antibiotic sensitivity.
In 2007, with a management change, the focus of the company changed from Research and Development to exploring how to capitalize on the company's existing intellectual property. It became obvious that the patents of the past possessed little monetary value for the future and that realization resulted in a further change in direction seeking to focus on practicality in research and a focus on a long term future return for the company and its shareholders. The period from 2007 through 2011 resulted in the abandonment of any focus on the production of hydrogen through bacteria degradation of organic waste utilizing what was referred to as a "bioreactor". The reason for the abandonment of the technology was the discovery of a lack of evidence for any economic potential for the technology. A similar discovery led to the practical abandonment of the NanoLogix BNC (BioNanoChannel) technology. While potentially a novel approach to diagnostics, major-lab third-party tests and a subsequent economic analysis demonstrated that under no conditions could the cost of both the antibody coating and specialized glass microchannel disc contained in the apparatus be reduced to a level to enable effective marketing. Over the following year, NanoLogix went through a transition to production of FlatPack™ Petri plates and BNP™ diagnostic test kits. Sales of both began in Q3 2012.
Rapid Diagnostics and the BNP™ and N-Assay.
NanoLogix' rapid diagnostic technologies are composed of one active method, the BNP, and one pending technology, the N-Assay modified ELISA diagnostic.
NanoLogix technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), Nanologix technology does not require large investments in equipment or personnel training.
Based on advancements in Petri dish technology, the company's BioNanoPore (BNP™), technology is simple, easy to use and portable. The company states that the kits provide a more accurate, cost-effective alternative to PCR and Flow Cytometry.
The benefits of Rapid diagnostics are far-reaching:
Test Results -- PARTIALLY UPDATED AS OF 01/31/2013-- FOR REFERENCE ONLY --
NanoLogix technology returns live-cell test results dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, the technology is stated to be easy-to-use and does not require large investments in equipment or personnel training.
NANOLOGIX RAPID DETECTION TIMES for ACTIVE THREAT MICROORGANISMS
Comparison of BNP™ and BNF™ with traditional Petri dish technology.
"NanoLogix Average" days/hours are based upon results achieved by NNLX through internal testing or results reported from independent third party tests. Detection time depends upon environmental conditions, sample quality, microorganism growth rates, nutrient concentrations, and many other factors. Actual results may vary.
*External third-party results
· Rapid diagnostics allow researchers in the lab to test for potentially pathogenic agents faster and develop effective countermeasures more rapidly and economically. This quality presents exciting opportunities in the pharmaceutical design process.
Can begin more effective drug treatment when an infectious disease is identified at an early stage. The spread of infectious disease may be reduced by earlier intervention.
·In combat theaters and homeland security settings, the presence of specific pathogens can be detected closer to the epicenter of release. Site decontamination teams can identify surface samples closer to real time, potentially aiding the field process.
Industrial production - of food, beverage, drugs, or beauty products - can be paralyzed by microbial contamination. The ripple effect may include expensive recalls, bad publicity, and government mandated "microbiology holds" that delay the replacement of product. Rapid diagnostics can help minimize the impact by limiting the spread of spoiled product.
The BNP™ Rapid test kit is the first of NanoLogix's inventions to go to market.
Advantages of BNP™
There are three main approaches to detection of microbes. The conventional approach uses the Petri dish to culture samples in agar. In general, this requires at least an 18 - 24 hour wait, in many instances much longer.
More recently, two other approaches have developed. One is PCR (Polymerase Chain Reaction), and the other Flow Cytometry.
PCR technology detects the DNA of a cell. Its shortcoming is the inability to distinguish between a live or dead cell. It cannot be used for the determination of the actual threat posed by a potentially dangerous microorganism. The process utilizes complicated opto-electronics computerized instrumentation, with an equipment acquisition price of approximately $100,000.
Until NanoLogix's BNP™ appeared, Flow Cytomery was the standard for "fast" detection. Though it can analyze one cell or particle in 1/10,000 of a second, it needs 18 hours (vs. 24 hours with the standard Petri dish) to provide accurate results. It is also expensive and requires special equipment and technicians.
With the advent of BNP's™ technology, rapid diagnostics has just gained an important new tool.
Based on Petri dish technology, the BNP™ provides a cheap, ultra-fast result in as little as one-third the time of the Flow Cytometry method, and one-quarter the time of the traditional Petri dish method. It distinguishes between live and dead cells (a crucial requirement in identifying dangerous microbes.) The technology is simple, easy to use, and portable. It provides viewable cultures for evaluation far faster than any other method in use.
The BioNanoPore (BNP™) kit employs a membrane that is extremely thin, translucent, water permeable, and capable of working with organic and non-organic molecules and proteins. The membrane is non-permeable to cell structures, non-toxic for cells, hydrophilic, and non-fluorescent. The BNP™ membrane is covered by a thin layer of solid nutrient media and can be used with nutrient agars of the type widely used in microbiological diagnostics.
How the BioNanoPore (BNP™) Membrane Works
Simple to use:
Inoculate microorganisms on BNP™ Petri-based isolator plate 1.
After a rapid incubation period, generally a fraction of traditional incubation times, transfer the BNP™ membrane to BNP™ staining plate 2.
Within minutes, micro-colonies are visible on staining plate.
The volume of Petri dishes used for traditional tests is millions per day worldwide. NanoLogix anticipates that the BNP™ Rapid technology will capture a portion of that market.
According to Industrial Microbiology Market Review, worldwide industrial microbiology testing is undergoing tremendous growth. The same growth pattern is anticipated in the medical microbiological diagnostics market.
NanoLogix's potential customers are numerous and varied. They include microbiological laboratories in the industrial, medical, environmental, governmental (federal, state and local) sectors, research and development facilities, and educational institutions.
NanoLogix's research and development continues on other diagnostic technology with variants in the N-Assay currently being developed for one of the world's largest Medical Device companies.
The patent information link:
Estimated Market Cap
- $8,410,892 as of December 31, 2015
As of 31 December 2015, the company has 140,181,530 shares outstanding. Outstanding on 12/31/14 were 139,531,530 shares.
Authorized Shares 200,000,000 as of Dec 31, 2015
Number of Share Holders of Record
- 2,000+/- shareholders as of end of 2015.
Float of 109,522,269 shares as of Dec 31, 2015
( 1 month daily, 3 month daily, 1 year weekly)
843 North Main Street
Hubbard, OH 44425 USA
330-534-0800 main line
Web site questions:
NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.
The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.
The BNP™ ultra-fast test kit sets a new standard for accurate, high-speed diagnostics. With results two to four times faster than traditional Petri dish methods, NanoLogix technology represents a revolutionary next step in disease identification.
Uses for NanoLogix's very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.
NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.